Global Nanoparticle Drug Delivery Systems Market Research Report 2022

Market Analysis and Insights: Global Nanoparticle Drug Delivery Systems Market
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.

LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
The global Nanoparticle Drug Delivery Systems market size is projected to reach US$ 8891.1 million by 2028, from US$ 4571.7 million in 2021, at a CAGR of 10.0% during 2022-2028.
Global Nanoparticle Drug Delivery Systems key players include Gilead Sciences, CSPC, Pacira, Alnylam, etc. Global top four manufacturers hold a share about 37%.
Asia-Pacific is the largest market, with a share about 37%, followed by Europe, and North America, both have a share over 56 percent.
In terms of product, Liposomes Drugs is the largest segment, with a share over 92%. And in terms of application, the largest application is Retail Pharmacy, followed by Hospital, etc.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nanoparticle Drug Delivery Systems market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nanoparticle Drug Delivery Systems market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nanoparticle Drug Delivery Systems market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nanoparticle Drug Delivery Systems market.
Global Nanoparticle Drug Delivery Systems Scope and Market Size
Nanoparticle Drug Delivery Systems market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Nanoparticle Drug Delivery Systems market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences

Frequently Asked Questions